Professor Dickon Hayne on bladder cancer data to watch for at ASCO 2025

In a recent interview with Urology Times®, Professor Dickon Hayne discussed some areas of ongoing development within bladder cancer that he finds particularly exciting ahead of this year’s American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois. At ASCO, Hayne will be presenting data on phase 3 trial of combination mitomycin/BCG in the high-risk non–muscle invasive bladder cancer (NMIBC) setting.

Hayne is a professor of urology at the University of Western Australia and the head of urology at Fiona Stanley Hospital in Perth, Australia.

During the interview, he began by noting the emergence of antibody drugs conjugates (ADCs) in urothelial cancer, which he finds particularly intriguing.

Hayne also touched on the potential role of ADCs in NMIBC, highlighting the EV-104 trial (NCT05014139) of enfortumab vedotin, as well as the SUBDUE trial,¹ which explored administration of checkpoint inhibitors directly into the bladder. The latter is appealing, he said, because of the potential to avoid the systemic adverse effects of immune therapies.

Hayne also expressed interest in data being presented in the metastatic setting, which he says may influence earlier-stage treatment strategies.

REFERENCE

1. Hayne D, Ong K, Swarbrick N, et al. The SUB-urothelial DUrvalumab InjEction-1 (SUBDUE-1) trial: first-in-human trial in patients with bladder cancer. BJU Int. 2024;134(2):283-290.

doi:10.1111/bju.16325